Sign in to view content

Characteristics and Outcomes of nAMD Patients Managed in US Routine Clinical Practice: Analysis of the IRIS Registry Database

Anita Barikian, MD

Video
Published 2022

Related

Baseline Characteristics of Patients Who Did or Did Not Maintain 12-Week and 16-Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial
Eric W Schneider, MD
Annual Meeting Talks
2023
Ladder Phase 2 Trial of the Port Delivery System With Ranibizumab (PDS) End of Study Results
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2020
Comparative Efficacy of Different Anti-VEGF Treatment Regimens in Patients With nAMD: A Network Meta-Analysis
Diana V Do, MD, FASRS
Annual Meeting Talks
2020

Category: AMD-Neovascular

See more